OncoMatch/Clinical Trials/NCT07860047
Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer
Official title: Randomized Phase II Study of Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Biochemical Relapse of Prostate Cancer
Is NCT07860047 recruiting? Yes, currently enrolling (Oct 2026). This Phase 2 trial studies multiple treatments including PSMAxCD3, bispecific antibody CC-1 and Multipeptide Vaccine VAC-XS15-PC01 for prostate cancer.
Treatment: PSMAxCD3, bispecific antibody CC-1 · Multipeptide Vaccine VAC-XS15-PC01 — This trial is a phase II, randomized, open label study designed to evaluate safety, tolerability and efficacy of CC-1, a bispecific antibody (bsAb) with PSMAxCD3 specificity, and of VACXS15-PC01, a prostate cancer (PC)-specific multi-peptide vaccine, both administered as single agent or in combination to patients affected with biochemical recurrence (BCR) of PC after local therapy with curative intent. Patients will not receive other treatments during trial participation.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: androgen deprivation treatment
Exception: testosterone has recovered to normal levels (>12 nmol/l)
Patients who are receiving or have previously received androgen deprivation treatment. Except testosterone has recovered to normal levels: patients who have previously received anti-hormonal treatment testosterone must be >12 nmol/l.
Cannot have received: salvage therapy (e.g. radiation)
Patients who are planned to or are undergoing salvage therapy (e.g. radiation)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07860047 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior androgen deprivation treatment, salvage therapy (e.g. radiation) disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages